A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Trial Title: A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

NCT ID: NCT06284486

Condition: Acute Myeloid Leukemia

Conditions: Official terms:
Venetoclax

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Venetoclax
Description: Given by PO
Arm group label: Venetoclax + Revumenib

Other name: ABT-199

Other name: GDC-0199

Intervention type: Drug
Intervention name: Revumenib
Description: Given by PO
Arm group label: Venetoclax + Revumenib

Other name: SNDX-5613

Summary: To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

Detailed description: Primary Objectives - Phase I: To determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of revumenib and venetoclax for patients with acute myeloid leukemia (AML) and detectable minimal or measurable residual disease (MRD). - Phase II: To assess the efficacy of the combination of venetoclax and revumenib in clearance of MRD in patients with AML. Secondary Objectives - To assess overall survival (OS), relapse-free survival (RFS), event-free survival (EFS) and duration of response (DOR). - To determine clinical flow and genetic MRD concordance rate Exploratory Objectives - To evaluate molecular and cellular markers that may be predictive of antitumor activity and/or resistance. - To correlate MRD negativity with clinical outcomes (survival and relapse risk) - To evaluate concordance of standard and novel MRD assays - To explore the safety and activity of venetoclax plus revumenib in the pediatric population

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age ≥ 12 years with weight ≥ 45Kg. 2. ECOG performance status of ≤ 2. 3. Leukemia status: - Known history of NPM1mt, or KMT2Ar, or NUP98r AML. - Bone marrow assessment showing no leukemia by morphology (blasts <5%) in first remission following high intensity chemotherapy or at least 2 cycles of low intensity therapy (e.g. hypomethylating agent or low-dose cytarabine-based), or in second remission following any therapy, with MRD ≥ 0.1% identified by multiparameter flow cytometry using central lab testing. - No clinically active extramedullary disease. 4. Baseline ejection fraction must be > 40%. 5. Adequate hepatic function (direct bilirubin < 1.5x upper limit of normal (ULN) unless increase is due leukemic involvement, and AST and/or ALT < 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5x ULN will be considered eligible). 6. Adequate renal function with an estimated glomerular filtration rate ≥ 60 mL/min based on local institutional practice for age-appropriate determination. 7. Able to swallow pills. 8. Participants or parent/guardian is willing and able to provide informed consent. Interval from prior treatment to time of initiation will be at least 14 days for cytotoxic or non-cytotoxic (immunotherapy agent(s), or an interval of 5 half-lives of the prior therapy, whichever is shorter. Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted. 9. Women of childbearing potential must agree to adequate methods of contraception during the study and at least 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and at least 3 months after the last treatment. Exclusion Criteria: 1. Prior treatment with a menin inhibitor. 2. Participants who are expected to receive standard therapy (either intensive or hypomethylating agent and venetoclax) with continued tolerability and benefit. 3. Participants who are expected to be able to proceed with stem cell transplantation within the next 30 days. 4. Participants with any concurrent uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the patient at unacceptable risk of study treatment. 5. The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled CNS leukemia. (2) use of hydroxyurea for patients with rapidly proliferative disease or for control of counts during differentiation syndrome. (3) use of steroids for treatment of differentiation syndrome. 6. Participants with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications. 7. Participants with a concurrent active malignancy under treatment. 8. Known active hepatitis B (HBV) or Hepatitis C (HCV) or HIV infection. 9. Female subjects who are pregnant or breast-feeding. 10. Participant has an active uncontrolled infection. 11. Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack. 12. QTc >450 msec for males and QTc >470 msec for females using the Fridericia Formula. 13. History of or any concurrent condition, therapy, or laboratory abnormality that in the Investigator's opinion might confound the results of the study, interfere with the participants's participation for the full duration of the study, or is not in the best interest of the patient to participate. 14. Clinically active central nervous system (CNS) leukemia. 15. Participants on immunosuppressive therapy post-HSCT at the time of screening (must be off all systemic immunosuppression therapy for at least 2 weeks and calcineurin inhibitors for at least 4 weeks). The use of topical steroids for cutaneous graft-versus-host disease (GVHD) or stable systemic steroid doses less than or equal to 20 mg of prednisone daily are permitted. 16. Participants with Grade > 2 active acute GVHD, moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity.

Gender: All

Minimum age: 12 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: MD Anderson Cancer Center

Address:
City: Houston
Zip: 77030
Country: United States

Status: Recruiting

Contact:
Last name: Ghayas Issa, MD

Phone: 713-745-6798
Email: gcissa@mdanderson.org

Investigator:
Last name: Ghayas Issa, MD
Email: Principal Investigator

Start date: September 23, 2024

Completion date: December 30, 2028

Lead sponsor:
Agency: M.D. Anderson Cancer Center
Agency class: Other

Collaborator:
Agency: Syndax Pharmaceuticals
Agency class: Industry

Collaborator:
Agency: Break Through Cancer
Agency class: Other

Collaborator:
Agency: AbbVie
Agency class: Industry

Source: M.D. Anderson Cancer Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06284486
http://www.mdanderson.org